Last reviewed · How we verify
NCT06828120
A Randomized, Safety and Efficacy Study of Taneasy 600mg Granules and Fluimucil 600mg Granules in COPD Subjects
Phase 4 trial testing Taneasy 600mg granules in COPD (Chronic Obstructive Pulmonary Disease) in 45 participants. Completed in 17 September 2025.
3 September 2025
Quick facts
| Lead sponsor | Bun Yao Biotechnology Co., Ltd |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 20 February 2025 |
| Primary completion | 3 September 2025 |
| Estimated completion | 17 September 2025 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Taneasy 600mg granules — full drug profile →
- Fluimucil 600mg granules — full drug profile →
Conditions studied
- COPD (Chronic Obstructive Pulmonary Disease) — all drugs for COPD (Chronic Obstructive Pulmonary Disease) →
Sponsor
Bun Yao Biotechnology Co., Ltd — full company profile →
Who can join
Adults 20 to 75, any sex, with COPD (Chronic Obstructive Pulmonary Disease). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety and efficacy of Taneasy 600mg granules and Fluimucil 600mg granules administered twice daily for 14 days in treatment of COPD Disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06828120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Taneasy 600mg granules
Trials testing the same drug.
- NCT06688292 — The Safety and Effectiveness of Taneasy and Actein in COPD Patients · Phase 4 · completed
Other recruiting trials for COPD (Chronic Obstructive Pulmonary Disease)
Currently open trials in the same condition.
- NCT07406048 — Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Bra · recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT07375433 — Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course a · recruiting
- NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
- NCT07031336 — Photon-counting CT in Chest Imaging · NA · recruiting
Other Bun Yao Biotechnology Co., Ltd trials
Trials by the same sponsor.
- NCT06688292 — The Safety and Effectiveness of Taneasy and Actein in COPD Patients · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06828120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bun Yao Biotechnology Co., Ltd
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06828120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing